Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action-Reference-Cited by-同舟云学术

Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action

Published:2022-11-02 Issue:12 Volume:13 Page:1839-1847
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Lückmann Michael¹^ORCID,Shenol Aslihan¹,Nissen Tinne A. D.²,Petersen Jacob E.¹,Kouvchinov David¹,Schwartz Thue W.¹,Frimurer Thomas M.¹^ORCID

Affiliation:

1. Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark

2. Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE5 9NU, U.K.

Funder

Novo Nordisk Fonden

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00160

Reference17 articles.

1. G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell

2. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study

3. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury

4. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development

5. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016–2019): a patent review

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?;Biomedicine & Pharmacotherapy;2024-03

2. G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children;Biomedicines;2023-05-29